A New Name in Weight-Loss Drugs

Motley Fool Hidden Gems Investing

The Motley Fool

Business, Investing

4.3 • 3.1K Ratings

🗓️ 20 May 2024

⏱️ 26 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Novo Nordisk and Eli Lilly have soared on GLP-1 weight-loss drugs – now Hims & Hers is trying to get in on the action with a more available and affordable option. (00:21) Asit Sharma and Dylan Lewis discuss: - Hims & Hers getting into the business of GLP-1 weight loss injections and what the compound market means for Novo Nordisk and Eli Lilly. - A sneaky company that’s another winner in the weight-loss market. - Wix’s successful pivot to a free-cash-flow orientation, and how the AI wave is pushing the company forward. (14:52) Gym stocks haven’t worked out for most investors, Ricky Mulvey caught up with Motley Fool analyst Sanmeet Deo to find out why he has cooled on one fast-growing gym franchisor and a space in fitness that is investable. Companies discussed: HIMS, NVO, MCK, LLY, Wix Host: Dylan Lewis Guests: Asit Sharma, Ricky Mulvey, Mary Long Producer: Ricky Mulvey Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	There's a new name in the hottest part of the weight loss market.
0:07.0	Motley Full Money starts now. I'm Dylan Lewis and I'm joined over the airwaves by Motley full analyst Osset Sharma.
0:25.0	Osset, thanks for joining me.
0:26.0	Dylan, happy to be here.
0:28.0	We've got two stocks up big today and we are digging into why.
0:32.0	The first one up Osset, online pharmacy. big today's
0:33.0	and we are digging into why the first one up, Osset, online pharmacy and
0:35.2	health care company Hymns and Hers, up over 30% as we record today's show on
0:39.9	news that they are expanding beyond some of the more conventional health and
0:43.9	wellness products, sexual health, hair loss treatments, and are going to be
0:47.6	offering compounded GLP1 weight loss injections. This seems to be them following a
0:54.4	playbook that they have established for other markets with what might be one of
0:57.9	the hottest medical treatments in the industry right now.
1:11.0	Dylan Hymns and hers offers personalized subscription care that can often be in the form of telehealth. So you sit with a doctor and then you get a prescription for medications.
1:14.5	They work with affiliated pharmacies and now have their own pharmacy manufacturing facilities.
1:20.0	So they're adding on GLP1 drugs to something that is already in play if you are a subscriber to Hymns and Hers.
1:27.2	They have a comprehensive weight loss program which seeks to treat weight loss in a holistic way.
1:33.2	It almost sounds like weight watchers,
1:35.9	if you followed the convolutions that weight watchers has had over the years,
1:39.1	sometimes it's focused on exercise,
1:40.5	sometimes it's focused on the diet, what you're eating. Sometimes it's
1:43.3	focused on medication. They sort of combine all of this. So they've got a group
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.